UBS lowered the firm’s price target on Arrowhead (ARWR) to $63 from $71 and keeps a Buy rating on the shares.
Don’t Miss TipRanks’ Half-Year Sale
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
- Make smarter investment decisions with TipRanks' Smart Investor Picks, delivered to your inbox every week.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on ARWR:
- Arrowhead Pharmaceuticals: Strong Financial Position with Pipeline Uncertainties Justifying Hold Rating
- Arrowhead Pharmaceuticals: Hold Rating Amid Promising Developments and Regulatory Uncertainties
- Arrowhead price target lowered to $17 from $21 at Citi
- Hold Rating for Arrowhead Pharmaceuticals Amid Revenue Gains and Market Uncertainties
- Arrowhead Pharmaceuticals Reports Strong Q2 2025 Results